2013 3Q This report is prepared to give investors a better understanding of Yuhan Corporation. Data in this report subject to change. 한 Copyright c 20

2013 3Q This report is prepared to give investors a better understanding of Yuhan Corporation. Data in this report subject to change. 한 Copyright c 2013 by YUHAN All rights Reserved Yuhan Corporation 49-6 Daebang Dongjak Seoul Korea 1

회사개요 Introduction Global Leading Healthcare Company Company profile Date of Foundation 1926. 6. 20 Date of IPO 1962. 11. 1 Founder 유일한 Major shareholder 유한재단 (15.4%) Number of Employees 1,519(R&D 300, 영업 700, 생산 170) Headquarter location 서울시동작구대방동 49-6 Plant location 충청북도청원군오창 Research Lab location 경기도용인시기흥 Branches 18 개지점 2

주요주주 Introduction ( 2012 년말 ) 주요주주주식수 % 유한재단 1,717,623 15.40% 국민연금 1,102,836 9.89% 유한학원 844,663 7.57% 자사주 833,002 7.47% Mattews Fund 652,774 5.85% 미래에셋자산 560,586 5.03% 연세대학교 414,900 3.72% 기타 5,026,162 45.1% TOTAL 11,152,546 100.00% 외국인 2,947,164 26.43% 3

매출구성 Business Overviews 2013 년매출계획 : 9,200 억원 처방약 (ETC) 63.4% 비처방약 (OTC) 12.6% 원료의약품 (API) 14.5% 임대 / 수탁제조 1.3% 생활용품 / 동물약품 8.7% 4

매출 / 이익 Business Overviews ( 단위 : 백만원 ) 구분 2011 년실적 2012 년실적 2013 년계획 금액금액 % 증감율 (%) 금액 % 증감율 (%) 비처방약 (OTC) 93,687 98,557 12.9 5.2 111,000 12.1 12.6 약품사업 처방약 (ETC) 401,097 459,727 60.3 14.6 583,700 63.4 27.0 소계 494,784 558,284 73.2 12.8 694,700 75.5 24.4 생활건강사업 71,808 73,165 9.6 1.9 80,000 8.7 9.3 수출 69,158 96,076 12.6 38.9 110,000 12.0 14.5 해외사업 ( 원료의약품 ) 내수 20,012 23,507 3.1 17.5 23,500 2.6 0.0 소계 89,170 119,583 15.7 34.1 133,500 14.5 11.6 기타 ( 임대 / 수탁 ) 매출액 영업이익 법인세차감전순이익 순이익 11,890 11,761 1.5-1.1 11,800 1.3 0.3 667,652 762,793 100.0 14.3 920,000 100.0 20.6 52,567 30,405 4.0-42.2 93,054 93,046 12.2 0.0 83,103 69,573 9.1-16.3 5

2013 분기실적 Business Overviews ( 단위 : 백만원 ) 구분 '13 1Q 증감율 '12 1Q '13 2Q 증감율 '12 2Q '13 3Q 증감율 '12 3Q '13 4Q 증감율 '12 4Q 비처방약 (OTC) 23,278 4.4% 22,304 24,682-9.1% 27,146 22,951-4.8% 24,102 25,005 약품 처방약 (ETC) 139,163 42.0% 97,978 152,419 26.8% 120,199 150,318 29.2% 116,327 125,223 소계 162,441 35.1% 120,282 177,101 20.2% 147,345 173,269 23.4% 140,429 150,228 생활건강사업 17,124-4.1% 17,854 18,959 6.3% 17,843 22,124 7.0% 20,675 16,793 해외 ( 원료의약품, API) 수출 28,862 70.8% 16,903 32,408 21.3% 26,726 19,765-38.0% 31,858 20,589 내수 3,973-52.8% 8,424 4,500-30.8% 6,502 3,487-25.9% 4,706 3,875 소계 32,835 29.6% 25,327 36,908 11.1% 33,228 23,252-36.4% 36,564 24,464 임대 / 수탁매출액영업이익배당금수익법인세차감전순이익순이익 3,154 2.2% 3,085 3,186 8.6% 2,934 3,050-6.1% 3,248 2,494 215,554 29.4% 166,548 236,154 17.3% 201,350 221,695 10.3% 200,916 193,979 12,080 19.1% 10,139 12,455 34.2% 9,280 11,503 269.0% 3,117 7,871 19,410-4.9% 20,401 18,000 35,886 11.2% 32,281 18,099 97.6% 9,160 11,051-35.8% 17,216 34,389 28,557 5.8% 27,002 13,342 420.4% 2,564 7,060-41.0% 11,975 28,033 배당금수익 : 13 1Q (Y-K 18,000 + J-K 1,410) / 12 1Q (Y-K 15,000 + J-K 5,400), 4Q(Y-K 18,000) 6

2013 주요제품실적 Business Overviews (1) 약품 ( 단위 : 억원 ) 구분 OTC( 비처방약 ) ETC( 처방약 ) 구분 2013 1-3Q 증감율 2012 1-3Q 2013 1-3Q 증감율 2012 1-3Q 삐콤 C,F 97-24.7% 128 트윈스타 ( 고혈압 ) 562 38.5% 406 머시론 ( 피임약 ) 84 19.3% 70 트라젠타 ( 당뇨병 ) 400 689.3% 51 안티푸라민 68 17.8% 58 비리어드 (B형간염) 368 2980.8% 12 비타민C 59 69.2% 35 아토르바 ( 고지혈 ) 256 8.1% 237 지르텍 44 1.3% 43 코푸시럽 ( 감기 ) 153 0.6% 152 염색약 23-5.1% 25 메로펜 ( 항생제 ) 143 2.4% 140 콘택골드 16-5.9% 17 프리베나13( 폐렴 ) 132 74.7% 75 바이오오일 15 - 알마겔 ( 제산제 ) 89-4.7% 93 그랑페롤 9-3.4% 9 암비솜 ( 항진균제 ) 98 21.8% 81 래피콜 8-14.1% 9 안플라그 ( 항혈전제 ) 80-0.8% 81 (2) 생활건강 (3) 원료의약품 ( 단위 : 억원 ) ( 단위 : 억원 ) 구분 2013 1-3Q 증감율 2012 1-3Q 구분 2013 1-3Q 증감율 2012 1-3Q 유한락스 382 5.5% 362 에이즈치료제 489 86.6% 262 암앤헤머 103 19.2% 86 항생제 95-39.1% 156 7

최근도입신제품 Divisional Strategies ( 단위 : 억원 ) 구분제품명적응증개발사출시일 2013 년목표 트윈스타 고혈압 베링거잉겔하임 Nov/10 휴물린 당뇨병 한국릴리 Jan/12 트루바다 에이즈 길리어드 Feb/12 처방약 트라젠타 당뇨병 베링거잉겔하임 Jun/12 2,500 프리베나13 폐렴구균백신 화이자 Jun/12 미카르디스 고혈압 베링거잉겔하임 Jun/12 비리어드 B형간염 길리어드 Dec/12 프라닥사 항응고제 베링거잉겔하임 Jan/13 8

R&D Pipeline Divisional Strategies 구분 효능 임상단계 Pre-Clinical Phase 1 Phase 2 Phase 3 고지혈당뇨복합 레바넥스복합 개량신약 고혈압고지혈복합 당뇨 중이염 바이오신약 퇴행성디스크 류마티스관절염 역류성식도염 신약 당뇨 과민성대장증후군 발기부전 천연물신약 천식 치주염 9

API Business( 원료의약품수출 ) (1) Divisional Strategies ( 단위 : 억원 ) 1,600 1,400 1,200 1,000 800 600 400 200-1,100 961 865 895 726 692 683 120 139 170 200 200 235 235 2007 2008 2009 2010 2011 2012 2013( P) 내수 수출 * Main item : HIV(US), HCV(US), 항생제 (US), 당뇨병 (Japan), Tamiflu( 조류독감 ) * API : active pharmaceutical ingredient 10

API Business( 원료의약품수출 ) (2) Divisional Strategies 1. Strategy : - 글로벌제약회사의신약임상단계에서부터개발에참여. 2. Diagram - Original 원료의주공급자로서장기공급및마진확보가가능. MNCs Original maker License owner YUHAN Contract Manufacturing for MNC(CMO) Develop new molecule 3. 신규원료공급을지속적으로추진중. 11

고정자산투자 / 세금혜택 Capex 설비투자, 감가상각비 (2006.5 월에신공장이전 ) 세금감면혜택 25 20 15 10 ( 십억 ) 22 15 18 14 19 12 21 10 18 6 ( 십억 ) 15 15 7 8 25 20 15 10 Tax rate(%) 30.0 25.0 20.0 15.0 10.0 19.3 9.9 10.8 9.2 9.7 10.7 25.2 23.0(E) 5 5 5.0-2006 2007 2008 2009 2010 2011 2012-2006 2007 2008 2009 2010 2011 2012 2013~2016(E) 설비투자감가상각비 12

지분법이익관계사 Affiliates 유한킴벌리킴벌리클라크와합작투자회사로서기저귀, 생리대, 화장지등을제조및판매하고있음. 국내최대시장점유율을유지하고있으며향후수출로써많은성장이예상됨. 유한크로락스미국크로락스와합작투자회사이며유한락스를제조하여유한양행에공급하고있음 유한화학유한양행의 100% 자회사이며원료의약품을생산하여유한양행에납품하고있음. cgmp 수준의설비를갖추고 FTC, PMH 등세계적인 API 를생산하고있음 유한메디카유한양행의 100% 자회사이며건강식품및젠텔등일부의약품을생산하여유한양행에공급하고있음 한국얀센존슨앤존슨과의합작투자회사이며지속적인제품을도입하여향후꾸준한성장이기대됨. 13

요약손익 Affiliates 1 영업실적 ( 단위 : 억원 ) 유한킴벌리유한화학유한메디카유한크로락스한국얀센 2011 13,041 581 131 330 2,234 2012 14,128 777 142 340 2,040 매출액 전년비증감 8.3% 33.7% 8.4% 3.0% -8.7% 2013 1-3Q 10,321 583 107 276 1,456 전년비증감 -3.7% -8.5% -0.5% 5.4% -13.6% 2011 1,353 10-2 40 350 O.P% 10.4% 1.7% -1.5% 12.1% 15.7% 2012 1,657 36 10 57 67 영업이익 O.P% 11.7% 4.6% 7.0% 16.8% 3.3% 2013 1-3Q 1,212 42 5 35 72 O.P% 11.7% 7.2% 4.7% 12.7% 4.9% 전년비증감 -9.2% 39.0% -27.8% 16.5% -43.5% 2011 1,119 12-16 35 251 N.I% 8.6% 2.1% -12.2% 10.6% 11.2% 2012 1,372 26 4 51 43 순이익 N.I% 9.7% 3.3% 2.8% 15.0% 2.1% 2013 1-3Q 1,007 34 2 31 32 N.I% 9.8% 5.8% 1.8% 11.2% 2.2% 전년비증감 -9.1% 32.4% -31.1% 18.2% -55.7% 유한지분 30.0% 100.0% 100.0% 50.0% 30.0% 2 배당금수익 / 지분법이익 유한킴벌리유한크로락스한국얀센 합계 ( 단위 : 억원 ) 2013 1-3Q 2012 1-3Q 배당금수익지분법이익배당금수익지분법이익 180 313 150 359 15 13 14 8 54 24 194 336 204 396 14

Appendix 1 : Statement of Financial position Appendix (Unit: KRW, Million) Item 2012.12.31 (K-IFRS) 2011.12.31 (K-IFRS) 2010.12.31 (K-IFRS) 1. Current assets 604,125 546,646 558,016 (1) Cash and Bank Deposits 336,822 295,322 326,489 (2) Trade Receivables 154,853 157,017 138,476 (3) Inventories 92,886 81,571 80,147 (4) Other current assets 19,564 12,736 12,904 2. Non-current assets 740,741 714,467 696,475 (1) Invesment Securities 146,568 118,145 102,184 (2) Equity-Method Company's stocks 309,870 314,370 309,870 (3) Tangible assets 267,848 266,304 270,333 (4) Intangible assets 8,405 9,240 6,961 (5) Other non-current assets 8,050 6,409 7,127 Assets 1,344,865 1,261,113 1,254,490 1. Trade Payables 79,965 69,292 66,275 2. Other current liabilities 70,494 53,695 60,455 3. Non-current liabilities 41,539 50,187 49,811 Liabilities 191,998 173,174 176,542 1. Capital stock 56,944 56,944 54,313 2. Retained earnings 1,008,493 952,226 880,313 3. Other Capital surplus 87,431 78,769 143,323 Shareholders' Equity 1,152,868 1,087,939 1,077,949 15

Appendix 2 : Income Statement Appendix (Unit: KRW, Million) Item 2012 (K-IFRS) 2011 (K-IFRS) 2010 (K-GAP) Amount % Change Amount % Change Amount % 1. Net sales 762,793 100.0% 14.3% 667,652 100.0% 2.8% 649,324 100.0% 2. Cost of sales 525,516 68.9% 25.4% 418,977 62.8% 9.7% 381,884 58.8% 3. Gross profit 237,277 31.1% -4.6% 248,676 37.2% -7.0% 267,440 41.2% 4. Selling and administrative expenses 206,872 27.1% 5.5% 196,109 29.4% 6.9% 183,471 28.3% 5. Operating profit 30,405 4.0% -42.2% 52,567 7.9% -37.4% 83,969 12.9% 6. Others profit 24,241 3.2% 178.8% 8,694 1.3% -58.9% 21,137 3.3% 7. Others expenses 15,606 2.0% 29.4% 12,058 1.8% -7.5% 13,040 2.0% 8. Finacial income 54,140 7.1% 23.1% 43,968 6.6% -27.7% 60,810 9.4% 9. Financial expenses 133 0.0% 14.6% 116 0.0% -95.8% 2,805 0.4% 10. Income before taxes 93,046 12.2% 0.0% 93,054 13.9% -38.0% 150,071 23.1% 11. Income taxes expense 23,472 3.1% 135.9% 9,951 1.5% -36.8% 15,749 2.4% 12. Net income 69,573 9.1% -16.3% 83,103 12.4% -38.1% 134,322 20.7% 16